- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Pharma Mar SAU (PHMR)
Pharma Mar SAU stock price live, this page displays BME PHMR stock exchange data. View the PHMR premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Pharma Mar SAU real time stock price chart below.
What Is the Pharma Mar SAU Stock Price Today?
The Pharma Mar SAU stock price today is 80.850.
What Is the Stock Symbol for Pharma Mar SAU?
The stock symbol for Pharma Mar SAU is ""PHMR.""
What Stock Exchange Does Pharma Mar SAU Trade On?
Pharma Mar SAU is listed and trades on the Madrid stock exchange.
Is Pharma Mar SAU a Good Stock to Buy?
Determining whether Pharma Mar SAU—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PHMR quote. (ISIN: ES0169501022)
What Is the Pharma Mar SAU Stock Price Today?
The Pharma Mar SAU stock price today is 80.850.
What Is the Stock Symbol for Pharma Mar SAU?
The stock symbol for Pharma Mar SAU is ""PHMR.""
What Stock Exchange Does Pharma Mar SAU Trade On?
Pharma Mar SAU is listed and trades on the Madrid stock exchange.
Is Pharma Mar SAU a Good Stock to Buy?
Determining whether Pharma Mar SAU—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PHMR quote. (ISIN: ES0169501022)
80.850
-3.750(-4.43%)
Delayed Data·
Fair Value
An estimate of a Pharma Mar's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
80.150
84.850
52 wk Range
37.400
105.800
PHMR Scorecard
Full Analysis
Impressive gross profit margins
PHMR is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Pharma Mar's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
80.15084.850
52 wk Range
37.400105.800
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.95%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.95%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
PHMR Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Pharma Mar's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Price Target
104.600
Upside
+29.38%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a high earnings multiple
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Pharma Mar SAU Company Profile
Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata for the treatment of soft tissue sarcoma and recurrent ovarian cancer; Aplidin is extracted from the ascidian Aplidium albicans for the treatment of relapsed multiple myeloma; and Zepzelca is a synthetic compound derived from a colonial ascidian to treat patients with metastatic small cell lung cancer, as well as in Phase IIb/III trials for the treatment of metastatic leiomyosarcoma. The company develops Ecubectedin (PM14), which is in phase I/II clinical trials with ecubectedin attained the optimal dose for the treatment of advanced solid tumors, as well as in Phase Ib trial with ecubectedin in combination with atezolizumab for the treatment of advanced solid tumors; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating choroidal neovascularization, such as macular degeneration and diabetic retinopathy; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.
Compare PHMR to Peers and Sector
Metrics to compare | PHMR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPHMRPeersSector | |
|---|---|---|---|---|
P/E Ratio | 0.0x | 8.3x | −0.6x | |
PEG Ratio | 0.00 | 0.05 | 0.00 | |
Price/Book | 0.0x | 2.1x | 2.6x | |
Price / LTM Sales | 0.0x | 4.3x | 3.3x | |
Upside (Analyst Target) | 0.0% | 35.2% | 39.1% | |
Fair Value Upside | Unlock | 13.5% | 4.5% | Unlock |
Analyst Ratings
3 Buy
2 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 104.600
(+29.38% Upside)
Earnings
Latest Release
Jul 30, 2025
EPS / Forecast
1.32 / 0.135
Revenue / Forecast
56.00M / 35.80M
People Also Watch
FAQ
What Stock Exchange Does Pharma Mar Trade On?
Pharma Mar is listed and trades on the Madrid Stock Exchange stock exchange.
What Is the Stock Symbol for Pharma Mar?
The stock symbol for Pharma Mar is "PHMR."
What Is the Pharma Mar Market Cap?
As of today, Pharma Mar market cap is 1.41B.
What Is Pharma Mar's Earnings Per Share (TTM)?
The Pharma Mar EPS (TTM) is 0.00.
When Is the Next Pharma Mar Earnings Date?
Pharma Mar will release its next earnings report on 10 Nov 2025.
From a Technical Analysis Perspective, Is PHMR a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Pharma Mar Stock Split?
Pharma Mar has split 7 times.
How Many Employees Does Pharma Mar Have?
Pharma Mar has 500 employees.
What is the current trading status of Pharma Mar (PHMR)?
As of 19 Aug 2025, Pharma Mar (PHMR) is trading at a price of 80.85, with a previous close of 84.60. The stock has fluctuated within a day range of 80.15 to 84.85, while its 52-week range spans from 37.40 to 105.80.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.